Therma Bright's Investment Partner Inretio Moves to New Manufacturing Facility
Toronto, Ontario--(Newsfile Corp. - March 8, 2023) - Investor partner Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. ("Inretio"), a leading Israeli medical device startup and developer of PREVA™ a novel clot removal device for ischemic stroke treatment. Inretio announced earlier this week it...
2023-03-08 7:51 AM EST
Therma Bright, Announces Appointment of Dr. John Patton as Chairman to Investee Company InStatin Inc.
Toronto, Ontario--(Newsfile Corp. - March 1, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge and proprietary diagnostic and medical technologies, is pleased to announce that Dr. John Patton has joined as Chairman of InStatin Inc.("InStatin") . InStatin is a privately-held innovative, research-based pharmaceutical company specializing in inhaled therapies, which is a recent Therma Bright investment. Dr. John...
2023-03-01 8:00 AM EST
Therma Bright Reports on Progress of Inretio's Novel Clot Removal Device for Stroke Treatment
Toronto, Ontario--(Newsfile Corp. - February 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. ("Inretio"), a leading Israeli medical device startup developing a novel clot removal device for use in treating ischemic stroke patients. Inretio recently announced promising results for...
2023-02-23 7:30 AM EST
Therma Bright Secures Exclusive License Agreement for AI4LYF's Patent-Pending Digital Cough Technology (DCT) to Detect Respiratory Diseases
Toronto, Ontario--(Newsfile Corp. - February 16, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has finalized and signed the exclusive worldwide licensing rights to market and sell AI4LYF's Digital Cough Technology (DCT). DCT can accurately and almost instantaneously detect...
2023-02-16 8:51 AM EST
Therma Bright Inc. Invests in Ischemic Stroke Blood Clot Retriever Technology Company Inretio Inc. based in Israel
Toronto, Ontario--(Newsfile Corp. - January 19, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd. ("Inretio") for its innovative protective blood clot retriever technology. Therma Bright has the right to invest up to USD...
2023-01-19 8:00 AM EST
Therma Bright Provides 2022 Year End Update
Toronto, Ontario--(Newsfile Corp. - December 21, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide a summary of activities and accomplishments achieved during 2022 as outlined below. AcuVid™ Health Canada continues to provide constructive feedback as the submission progresses through their approval...
2022-12-21 8:00 AM EST
Therma Bright investiert in die entwicklung neuartiger behandlungen für COVID-19, asthma und chronisch obstruktive lungenerkrankung (COPD)
Toronto, Ontario--(Newsfile Corp. - Freitag, 2. Dezember 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" oder das "Unternehmen"), Entwickler eines intelligenten AcuVid™ COVID-19 Antigen-Speichel-Schnelltests und anderer fortschrittlicher Diagnose- und Medizingerätetechnologien, freut sich, den Abschluss einer Übernahmevereinbarung bekannt zu geben. Dabei geht es um einen Anteilserwerb an einer neuartigen Technologie für den Einsatz inhalierter Statine zur Behandlung von...
2022-12-02 5:52 PM EST
Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into an agreement to acquire an interest in a novel technology that utilizes inhaled statins for the treatment of respiratory conditions including asthma, chronic obstructive...
2022-12-01 8:02 AM EST
Therma Bright Inc. to Acquire an Exclusive License for a Patented Digital Cough Based Technology to Detect Respiratory Diseases
Toronto, Ontario--(Newsfile Corp. - November 17, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent ("LOI") with AI4LYF LLC ("AI4LYF") for the exclusive licensing rights for a digital cough-based diagnosis screening technology. Digital Cough Test...
2022-11-17 7:30 AM EST
Therma Bright Receives New Billing Codes for Venowave Allowing for Reimbursement from Medicare, Medicaid, and Private Insurers
Toronto, Ontario--(Newsfile Corp. - October 27, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has received new temporary PDAC (Pricing, Data Analysis and Coding) billing codes for its Venowave product giving Therma Bright immediate access to reimbursement through Medicare and Medicaid....
2022-10-27 7:30 AM EDT
Therma Bright Receives Payment for Initial Venowave Sales
Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that the initial order of its updated Venowave product has been sold to customers in the US by our exclusive distributor, DME Authority. Therma Bright is pleased to announce it has received payment...
2022-09-20 8:05 AM EDT
Therma Bright Provides Update on FDA EUA Review Process
Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, provides an update on it AcuVid™ COVID-19 Rapid Antigen Saliva Test's Emergency Use Authorization application with the U.S. Food and Drug Administration. The Company has received communication from the FDA which states they have completed...
2022-09-12 8:28 AM EDT
Therma Bright Provides Progress Update on FDA EUA & Health Canada Interim Order Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - August 4, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide the following update for Its AcuVid™ COVID-19 Rapid Antigen Saliva Test. Therma continues to communicate with the FDA regarding its EUA application for its AcuVid™ COVID-19 Rapid Antigen Saliva Test. As...
2022-08-04 7:00 AM EDT
Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)
Toronto, Ontario--(Newsfile Corp. - June 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its Health Canada application for the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point-of-Care Use (PoC). The HC application includes all the updated data from the...
2022-06-23 4:34 PM EDT
Therma Bright Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - June 10, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, announces that it has granted incentive stock options to certain directors, officers and consultants of the Company to purchase up to an aggregate of 1,475,000 common shares of the Company pursuant to the Company's share option plan. The options are...
2022-06-10 7:48 AM EDT
Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - June 2, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, is pleased to provide an update for the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test and its U.S. Food and Drug Administration's Emergency Use Authorization application process. The Company's Executive and Product Development teams have been working...
2022-06-02 7:30 AM EDT
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - May 10, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it will submit an application to Health Canada for review of the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test for detecting SARS CoV-2 virus in saliva. The application to Health Canada follows an application under the Emergency Use Authorization (EUA) guidelines to the U.S. Food & Drug...
2022-05-10 7:30 AM EDT
Therma Bright Ships Initial Venowave Order to US Distributor
Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, is pleased to announce that the initial order of its updated Venowave product has been shipped to its US distributor, DME Authority, LLC, from Therma's Chinese contract manufacturer. As previously announced on December 16, 2021 the initial order consists of 2,500...
2022-04-28 8:07 AM EDT
Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration's Emergency Use Authorization (EUA)
Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) application for its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (POC). "I am...
2022-03-29 8:30 AM EDT
Therma Bright Recognized In 2022 TSX Venture 50 Top Performing Stocks
Toronto, Ontario--(Newsfile Corp. - February 24, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the Company has been recognized in the 2022 TSX Venture 50 for top performing stocks, and ranked in the top three (3) for the Life Sciences sector. The 2022 TSX Venture 50 winners were selected based...
2022-02-24 7:30 AM EST